Literature DB >> 7128007

Effects of cancer and its treatments on plasma concentration of alpha 1-acid glycoprotein and propranolol binding.

F P Abramson, J Jenkins, Y Ostchega.   

Abstract

The plasma concentrations of alpha 1-acid glycoprotein (AAG) and albumin, and the plasma protein binding of propranolol were measured in a group of cancer patients and a group of normal subjects. In cancer patients the AAG concentrations were twice that in controls (142 and 78 mg/dl, P less than 0.005), the albumin concentrations were lower (3.11 and 4.37 gm/dl, P less than 0.001), and the free fraction of propranolol was lower (0.127 and 0.190, P less than 0.005). Propranolol binding correlated strongly with AAG concentrations. These data imply that untreated or unsuccessfully treated cancer patients will have reduced free fractions for any drug for which AAG is an important binding protein. Successfully treated patients may have longitudinal changes towards normal. No consistent effect of the treatments themselves on AAG was observed after radiation therapy in five patients or after intravenous adriamycin in six patients.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7128007     DOI: 10.1038/clpt.1982.218

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  11 in total

Review 1.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

2.  Influence of menstrual cycle phase on serum concentrations of alpha 1-acid glycoprotein.

Authors:  R C Parish; C Spivey
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

3.  Variation in serum binding of tertatolol mediated by disease-induced modification of alpha-acid glycoprotein concentration.

Authors:  S Urien; D Morin; A Renouard; I Rocher; J P Tillement
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  Differential effect of cancer on the serum protein binding to mianserin and imipramine.

Authors:  I Torres; E Suárez; J M Rodríguez-Sasiain; C Aguirre; R Calvo
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1995 Apr-Jun       Impact factor: 2.441

5.  Effect of age and sex on the plasma binding of acidic and basic drugs.

Authors:  R K Verbeeck; J A Cardinal; S M Wallace
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

6.  Decrease in penbutolol protein binding as a consequence of treatment with some alkylating agents.

Authors:  C Aguirre; J M Rodríguez-Sasiain; R Calvo
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 7.  Free drug concentration monitoring in clinical practice. Rationale and current status.

Authors:  C K Svensson; M N Woodruff; J G Baxter; D Lalka
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

8.  A simple and rapid fluorometric determination method of alpha 1-acid glycoprotein in serum using quinaldine red.

Authors:  H Imamura; T Maruyama; H Okabe; H Shimada; M Otagiri
Journal:  Pharm Res       Date:  1994-04       Impact factor: 4.200

9.  Melphalan concentration dependent plasma protein binding in healthy humans and rats.

Authors:  N H Greig; D J Sweeney; S I Rapoport
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

10.  Protein binding of brequinar in the plasma of healthy donors and cancer patients and analysis of the relationship between protein binding and pharmacokinetics in cancer patients.

Authors:  S Y King; A M Agra; H S Shen; C L Chi; D B Adams; V E Currie; J R Bertino; H J Pieniaszek; C Y Quon
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.